Emergent BioSolutions Shares Rise on U.S. Smallpox-Treatment Order

Dow Jones

Sep 27, 2024

By Josh Beckerman

Emergent BioSolutions shares surged after the company reported a $67.4 million order for smallpox treatment Tembexa under an existing 10-year U.S. government contract.

Shares of the Gaithersburg, Md., maker of medical countermeasures were recently up 19% at $7.07. The stock has nearly tripled since the start of the year.

The company said the exercise of two procurement options commits funding through 2027.

Emergent shares also rose Wednesday after an update about 2024 and 2025 orders, but ended the day down 3%.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

September 26, 2024 14:07 ET (18:07 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2470763466"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2470763466\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2470763466?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-27 02:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2470763466","market":"fut","top_or_hot":-1,"title":"Emergent BioSolutions Shares Rise on U.S. Smallpox-Treatment Order","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Emergent BioSolutions shares surged after the company reported a $67.4 million order for smallpox treatment Tembexa under an existing 10-year U.S. government contract. \n</p>\n<p>\n  Shares of the Gaithersburg, Md., maker of medical countermeasures were recently up 19% at $7.07. The stock has nearly tripled since the start of the year. \n</p>\n<p>\n  The company said the exercise of two procurement options commits funding through 2027. \n</p>\n<p>\n  Emergent shares also rose Wednesday after an update about 2024 and 2025 orders, but ended the day down 3%. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 26, 2024 14:07 ET (18:07 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Emergent BioSolutions Shares Rise on U.S. Smallpox-Treatment Order</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEmergent BioSolutions Shares Rise on U.S. Smallpox-Treatment Order\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-09-27 02:07</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Emergent BioSolutions shares surged after the company reported a $67.4 million order for smallpox treatment Tembexa under an existing 10-year U.S. government contract. \n</p>\n<p>\n  Shares of the Gaithersburg, Md., maker of medical countermeasures were recently up 19% at $7.07. The stock has nearly tripled since the start of the year. \n</p>\n<p>\n  The company said the exercise of two procurement options commits funding through 2027. \n</p>\n<p>\n  Emergent shares also rose Wednesday after an update about 2024 and 2025 orders, but ended the day down 3%. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 26, 2024 14:07 ET (18:07 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EBS","symbol_name":"Emergent Biosolutions","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2470763466","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2470763466","pubTimestamp":1727374020,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Emergent BioSolutions shares surged after the company reported a $67.4 million order for smallpox treatment Tembexa under an existing 10-year U.S. government contract.Shares of the Gaithersburg, Md., maker of medical countermeasures were recently up 19% at $7.07. The stock has nearly tripled since the start of the year.The company said the exercise of two procurement options commits funding through 2027.Emergent shares also rose Wednesday after an update about 2024 and 2025 orders, but ended the day down 3%.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EBS":"Emergent Biosolutions","BK4139":"生物科技","BK4583":"猴痘概念"},"translate_title":"Emergent BioSolutions股价因美国天花治疗令而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EBS":1},"content_text":"By Josh Beckerman \n\n\n \n\n\n  Emergent BioSolutions shares surged after the company reported a $67.4 million order for smallpox treatment Tembexa under an existing 10-year U.S. government contract. \n\n\n  Shares of the Gaithersburg, Md., maker of medical countermeasures were recently up 19% at $7.07. The stock has nearly tripled since the start of the year. \n\n\n  The company said the exercise of two procurement options commits funding through 2027. \n\n\n  Emergent shares also rose Wednesday after an update about 2024 and 2025 orders, but ended the day down 3%. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 26, 2024 14:07 ET (18:07 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}